Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir in Moderate to Severe COVID-19
NCT04529499Phase 3Terminated
- Sponsor
- Dr. Reddy's Laboratories
- Start
- Aug 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of favipiravir in coronavirus disease 2019 (COVID-19), sponsored by Dr. Reddy's Laboratories. Started Aug 2020; status: terminated.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04529499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04529499.